Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure.

Mlineritsch, B; Mayer, P; Rass, C; Reiter, E; Russ, G; Vesenmayer, G; Oberaigner, W; Hausmaninger, H

Mlineritsch, B; Mayer, P; Rass, C; Reiter, E; Russ, G; Vesenmayer, G; Oberaigner, W; Hausmaninger, H.

Affiliation

Mlineritsch B; Innere Medizin 3, Onkologische Abteilung, St. Johanns-Spital Salzburg, Austria. b.mlineritsch@lks.at

Onkologie ; 27(5): 441-6, 2004 Oct.

Article in En | MEDLINE | ID: mdl-15585973

Subject(s)

Bone Neoplasms/drug therapy; Bone Neoplasms/mortality; Breast Neoplasms/drug therapy; Breast Neoplasms/mortality; Doxorubicin/administration & dosage; Liver Neoplasms/drug therapy; Liver Neoplasms/mortality; Adult; Aged; Antibiotics, Antineoplastic/administration & dosage; Austria/epidemiology; Bone Neoplasms/diagnosis; Bone Neoplasms/secondary; Breast Neoplasms/diagnosis; Delayed-Action Preparations/administration & dosage; Disease-Free Survival; Female; Humans; Liver Neoplasms/diagnosis; Liver Neoplasms/secondary; Lymphatic Metastasis; Middle Aged; Polyethylene Glycols; Survival Analysis; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Breast Neoplasms / Doxorubicin / Liver Neoplasms Type of study: Diagnostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Onkologie Year: 2004 Document type: Article Affiliation country: Austria Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links